← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	26 Vericel Corp VCEL $2.12B	129	+45	+54%	$317M
27	27 Voyager Therapeutics VYGR $126M	125	+17	+16%	$569M
28	28 Atara Biotherapeutics ATRA $98.1M	124	+10	+9%	$1.71B
29	29 Arrowhead Research ARWR $8.12B	116	+24	+26%	$703M
30	30 Lineage Cell Therapeutics LCTX $248M	107	-8	-7%	$113M
31	ATHX 31 DELISTED Athersys, Inc. Common Stock ATHX	104	+10	+11%	$52M
32	32 CareDx CDNA $3.45B	104	+31	+42%	$324M
33	33 Fate Therapeutics FATE $231M	103	+13	+14%	$488M
34	NVTA 34 DELISTED Invitae Corporation NVTA	101	+7	+7%	$375M
35	35 DELISTED Adverum Biotechnologies ADVM	100	+4	+4%	$194M
36	36 Pacific Biosciences PACB $609M	99	-2	-2%	$331M
37	37 uniQure QURE $1.51B	97	+28	+41%	$833M
38	BLCM 38 DELISTED Bellicum Pharmaceuticals, Inc. BLCM	96	+6	+7%	$189M
39	39 Abeona Therapeutics ABEO $267M	92	+4	+5%	$585M
40	ADAP 40 DELISTED Adaptimmune Therapeutics ADAP	86	+10	+13%	$663M
41	41 Cellectis CLLS $111M	86	+17	+25%	$319M
42	42 Standard BioTools LAB $259M	84	0	0%	$227M
43	NSTG 43 DELISTED NanoString Technologies, Inc. NSTG	81	+4	+5%	$299M
44	44 Lakefront Biotherapeutics American Depositary Shares LKFT $1.97B	79	-3	-4%	$698M
45	45 Wave Life Sciences WVE $617M	78	-1	-1%	$936M
46	46 Rocket Pharmaceuticals RCKT $257M	76	+20	+36%	$664M
47	47 Veracyte VCYT $3.61B	75	-5	-6%	$231M
48	ISEE 48 DELISTED IVERIC bio, Inc. Common Stock ISEE	73	+2	+3%	$55.6M
49	PTE 49 DELISTED PolarityTE, Inc. Common Stock PTE	73	+38	+109%	$217M
50	50 Invesco Biotechnology & Genome ETF PBE $430M	72	-2	-3%	$54.4M